Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

Authors: Chiharu Tabata, Eisuke Shibata, Rie Tabata, Shingo Kanemura, Koji Mikami, Yoshitaka Nogi, Eriko Masachika, Tomoyuki Nishizaki, Takashi Nakano

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to conventional chemotherapy and radiotherapy. Therefore, diagnosing MPM early is very important. Some researchers have previously reported that high-mobility group box 1 (HMGB1) was correlated with pulmonary fibrosis. MPM involves the malignant transformation of mesothelial cells, which originate from mesenchymal cells similar to lung fibroblasts. Here, we investigated serum levels of HMGB1 in patients with MPM and compared them with those of a population that had been exposed to asbestos without developing MPM.

Methods

HMGB1 production from MPM cell lines was measured using ELISA. Serum HMGB1 levels were also examined in 61 MPM patients and 45 individuals with benign asbestos-related diseases.

Results

HMGB1 concentrations of 2 out of 4 MPM cell lines were higher than that of normal mesothelial cell line, Met-5A. We demonstrated that patients with MPM had significantly higher serum levels of HMGB1 than the population who had been exposed to asbestos but had not developed MPM. The difference in overall survival between groups with serum HMGB1 levels that were lower and higher than assumed cut-off values was significant.

Conclusions

Our data suggest that serum HMGB1 concentration is a useful prognostic factor for MPM.
Appendix
Available only for authorised users
Literature
1.
Robinson BW, Musk AW, Lake RA: Malignant mesothelioma. Lancet. 2005, 366: 397-408. 10.1016/S0140-6736(05)67025-0.CrossRefPubMed
2.
Robinson BW, Lake RA: Advances in malignant mesothelioma. N Engl J Med. 2005, 353: 1591-1603. 10.1056/NEJMra050152.CrossRefPubMed
3.
Wagner JC, Sleggs CA, Marchand P: Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960, 17: 260-271.PubMedPubMedCentral
4.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21: 2636-2644. 10.1200/JCO.2003.11.136.CrossRefPubMed
5.
Nowak AK, Lake RA, Kindler HL, Robinson BW: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002, 29: 82-96. 10.1053/sonc.2002.30234.CrossRefPubMed
6.
Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003, 362: 1612-1616. 10.1016/S0140-6736(03)14794-0.CrossRefPubMed
7.
Hollevoet K, Reitsma JB, Creaney J: Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012, 30: 1541-1549. 10.1200/JCO.2011.39.6671.CrossRefPubMedPubMedCentral
8.
Bianchi ME, Beltrame M, Paonessa G: Specific recognition of cruciform DNA by nuclear protein HMG1. Science. 1989, 243 (4894 Pt 1): 1056-1059.CrossRefPubMed
9.
Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002, 418 (6894): 191-195. 10.1038/nature00858.CrossRefPubMed
10.
He M, Kubo H, Ishizawa K, Hegab AE, Yamamoto Y, Yamamoto H, Yamaya M: The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L1427-L1436. 10.1152/ajplung.00075.2007.CrossRefPubMed
11.
Hamada N, Maeyama T, Kawaguchi T, Yoshimi M, Fukumoto J, Yamada M, Yamada S, Kuwano K, Nakanishi Y: The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008, 39: 440-447. 10.1165/rcmb.2007-0330OC.CrossRefPubMed
12.
Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995, 108: 1122-1128.CrossRefPubMed
13.
Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005, 5: 331-3342. 10.1038/nri1594.CrossRefPubMed
14.
Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001, 108: 949-955.CrossRefPubMedPubMedCentral
15.
Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H: Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med. 2006, 203: 1637-1642. 10.1084/jem.20052203.CrossRefPubMedPubMedCentral
16.
Takahashi K, Fukushima S, Yamahara K, Yashiro K, Shintani Y, Coppen SR, Salem HK, Brouilette SW, Yacoub MH, Suzuki K: Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation. 2008, 118 (14 Suppl): S106-S1014.CrossRefPubMed
17.
Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003, 48: 971-981. 10.1002/art.10859.CrossRefPubMed
18.
Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, O'Neal W, Sorscher EJ, Abraham E, Blalock JE: Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med. 2008, 178: 822-831. 10.1164/rccm.200712-1894OC.CrossRefPubMedPubMedCentral
19.
Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007, 13: 2836-2848. 10.1158/1078-0432.CCR-06-1953.CrossRefPubMed
20.
21.
Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000, 405: 354-360. 10.1038/35012626.CrossRefPubMed
22.
Poser I, Golob M, Buettner R, Bosserhoff AK: Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol. 2003, 23: 2991-2998. 10.1128/MCB.23.8.2991-2998.2003.CrossRefPubMedPubMedCentral
23.
Völp K, Brezniceanu ML, Bösser S, Brabletz T, Kirchner T, Göttel D, Joos S, Zörnig M: Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2006, 55: 234-242. 10.1136/gut.2004.062729.CrossRefPubMedPubMedCentral
24.
Brezniceanu ML, Völp K, Bösser S, Solbach C, Lichter P, Joos S, Zörnig M: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003, 17: 1295-1297.PubMed
25.
Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng YJ, Lin FY, Chen YL, Hung CY, Chen WC, Chen YH, Chong IW: High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol. 2010, 43: 530-538. 10.1165/rcmb.2009-0269OC.CrossRefPubMed
26.
Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J: Occupational, domestic and environmental mesothelioma risks in the British population: a case–control study. Br J Cancer. 2009, 100: 1175-1183. 10.1038/sj.bjc.6604879.CrossRefPubMedPubMedCentral
27.
Selikoff IJ, Hammond EC, Seidman H: Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 1980, 15: 2736-2740.CrossRef
28.
Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M: TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA. 2006, 103: 10397-10402. 10.1073/pnas.0604008103.CrossRefPubMedPubMedCentral
29.
Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, Pass HI, Yang H: Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012, 227: 44-58. 10.1002/jcp.22724.CrossRefPubMedPubMedCentral
30.
Carbone M, Yang H: Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res. 2012, 18: 598-604. 10.1158/1078-0432.CCR-11-2259.CrossRefPubMed
Metadata
Title
Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma
Authors
Chiharu Tabata
Eisuke Shibata
Rie Tabata
Shingo Kanemura
Koji Mikami
Yoshitaka Nogi
Eriko Masachika
Tomoyuki Nishizaki
Takashi Nakano
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-205

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization

Research article

Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors

Study protocol

Early-stage squamous cell carcinoma of the oropharynx: Radiotherapy vs. Trans-Oral Robotic Surgery (ORATOR) – study protocol for a randomized phase II trial

Research article

Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53

Research article

Tumor necrosis factor-α attenuates starvation-induced apoptosis through upregulation of ferritin heavy chain in hepatocellular carcinoma cells

Research article

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits